General Electric Company (NYSE:GE)
On Monday, General Electric Company (NYSE:GE)’s shares inclined 0.26% to $30.36.
GE offered 8.80% EPS for prior five years. The company has -6.40% return on equity value while its ROI ratio was 3.60%. The company has $306.11 billion market capitalizations and the institutional ownership was 57.00%. Its price to book ratio was 2.76. Volatility of the stock was 2.39% for the week while for the month booked as 1.85%.
The mean estimate for the short term price target for General Electric Company (NYSE:GE) stands at $30.62 according to 13 Analysts. The higher price target estimate for the stock has been calculated at $33.00 while the lower price target estimate is at $27.00.
Analysts mean recommendation for the stock is 2.10. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
General Electric Company (GE) is a diversified infrastructure and financial services company. The products and services of the Company range from aircraft engines, power generation, oil and gas production equipment, and household appliances to medical imaging, business and consumer financing and industrial products.
AstraZeneca plc (ADR) (NYSE:AZN)
AstraZeneca plc (ADR) (NYSE:AZN)’s shares gained 4.76% to $32.78.
AZN has beta value of 0.78. The company has the market capitalization of $78.80 billion. Return on assets ratio of the company was 3.10% while its return on equity ratio was 9.40%. ATR value of company was 0.67 while stock volatility for week was 2.02% while for month was 1.62%. Debt to equity ratio of the company was -0.63 and its current ratio was -0.80.
The mean estimate for the short term price target for AstraZeneca plc (ADR) (NYSE:AZN) stands at $30.86 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $40.45 while the lower price target estimate is at $34.00.
Analysts mean recommendation for the stock is 2.50. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal.
Norwegian Cruise Line Holdings Ltd (NASDAQ:NCLH)
At the end of Monday’s trade, Norwegian Cruise Line Holdings Ltd (NASDAQ:NCLH)‘s shares dipped -1.58% to $54.33.
NCLH is currently valued at $12.67 billion. The company has 229.47 million shares outstanding and 79.60% shares of the company were owned by institutional investors. The company has 3.04 value in price to sale ratio while price to book ratio was recorded as 3.15. The company exchanged hands with 2.26 million shares as compared to its average daily volume of 1.15 million shares.
The mean estimate for the short term price target for Norwegian Cruise Line Holdings Ltd (NASDAQ:NCLH) stands at $65.71 according to 14 Analysts. The higher price target estimate for the stock has been calculated at $73.00 while the lower price target estimate is at $35.00.
Analysts mean recommendation for the stock is 2.10. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Norwegian Cruise Line Holdings Ltd. is a diversified cruise operator. The Company operates cruise lines under the Norwegian, Oceania and Regent brands. Norwegian offers cruises ranging in length from one day to three weeks.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.